Drug Profile
Research programme: eye disorder therapeutics - Imagen Biotech
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Imagen Biotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Eye disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Age-related-macular-degeneration in USA
- 16 Jul 2016 No recent reports of development identified for research development in Eye-disorders in USA
- 19 Oct 2011 Research programme: eye disorder therapeutics - Imagen Biotech is available for partnering in World as of 19 Oct 2011. http://www.imagenbiotech.com